#5: ANDS Stock News : Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
ANA598 To Be Dosed for 12 Weeks in Triple Combination
SAN DIEGO, July 30 /PRNewswire-FirstCall/ -- Anadys
Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced finalization of
the protocol...
Data Being Presented Today at 44th Annual Meeting of EASL
Management to Discuss Study Results and Program Status During Q1 Financial Results Call at 5 P.M. EDT Today
SAN DIEGO,...
SAN DIEGO, Oct. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at BIO InvestorForum 2007 on Wednesday, October 10, 2007, at...
#2: Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS Stock Forums), a biopharmaceutical company committed to the discovery, development and commercialization of novel medicines for the treatment of hepatitis...